APA (7th ed.) Citation

Martin, D., Stevenson, L., Prasad, P., Smirnakis, K., Kao, A., Rabah, D., . . . Franchimont, N. (2017). SAT0235 BIIB059, a monoclonal antibody targeting BCDA2 shows safety, tolerability, pharmacokinetics, pharmacodynamics in healthy volunteer subjects. Annals of the rheumatic diseases, 76(Suppl 2), 862. https://doi.org/10.1136/annrheumdis-2017-eular.6109

Chicago Style (17th ed.) Citation

Martin, D., et al. "SAT0235 BIIB059, a Monoclonal Antibody Targeting BCDA2 Shows Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteer Subjects." Annals of the Rheumatic Diseases 76, no. Suppl 2 (2017): 862. https://doi.org/10.1136/annrheumdis-2017-eular.6109.

MLA (9th ed.) Citation

Martin, D., et al. "SAT0235 BIIB059, a Monoclonal Antibody Targeting BCDA2 Shows Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteer Subjects." Annals of the Rheumatic Diseases, vol. 76, no. Suppl 2, 2017, p. 862, https://doi.org/10.1136/annrheumdis-2017-eular.6109.